Welcome to our dedicated page for DarioHealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on DarioHealth stock.
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
DarioHealth's holistic approach offers continuous and customized care, disrupting the traditional episodic approach to healthcare. The company empowers people to adapt their lifestyles for sustainable behavior change, driving exceptional satisfaction, retention, and results. Dario's solutions are globally available to health plans, self-insured employers, care providers, and consumers.
One of DarioHealth's latest achievements includes the acquisition of Twill, Inc., a move that nearly doubles its pro forma revenues for 2023 and enhances its ability to deliver comprehensive digital health solutions. The integration of Twill is expected to create immediate scale, boost gross margins to approximately 80-85% by 2025, and accelerate the path to profitability through significant cost synergies.
Recent news highlights include Dario's partnership with Blue Shield of California to make its award-winning digital health platform, Wellvolution, more accessible to Spanish speakers. This initiative aims to close care gaps in underserved communities by offering personalized solutions for hypertension, diabetes, weight management, and mental health support. Additionally, Dario announced a new contract to provide its cardiometabolic solution to a regional union, further expanding its presence in the public and labor sectors.
DarioHealth's clinical research continuously demonstrates the efficacy of its digital solutions. For instance, a recent study published in the Journal of Internet Medicine (JMIR) showed significant reductions in blood glucose levels and BMI for members using Dario's weight monitoring features. Other studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes highlighted the company's ability to deliver improved health outcomes through integrated solutions.
Financially, DarioHealth reported strong performance in Q1 2024, with revenues of $5.8 million driven by growth in its Business-to-Business-to-Consumer (B2B2C) model. The company continues to launch new customer partnerships and expects further revenue growth throughout 2024.
With a strong cash position and ongoing innovation, DarioHealth is well-prepared to execute its strategy and solidify its leadership in the digital health space.
DarioHealth Corp. (NASDAQ: DRIO) announced a partnership with a major Northeast supermarket chain to enhance employees' cardiometabolic health starting in Q1 2023. This contract marks Dario's achievement of 100 enterprise contracts, validating its strategic position in the digital therapeutics market. The suite focuses on managing diabetes, hypertension, and weight management via integrated solutions. The Company anticipates growth due to increasing demand for multi-condition solutions from enterprise customers.
DarioHealth Corp. (NASDAQ: DRIO) announced a study published in Frontiers in Physiology on Dec. 19, 2022, showcasing its musculoskeletal solution's effectiveness in alleviating back pain. The research analyzed data from 981 users over eight weeks, revealing a 50% average reduction in pain, with 60% of users reporting significant relief after four weeks. The device offers real-time biofeedback to improve posture, resulting in better pain management. Dario's commitment to changing health management behaviors through innovative technology is emphasized, showing potential for chronic pain treatment.
DarioHealth Corp. (Nasdaq: DRIO) announced participation in two upcoming investor conferences. The 13th Annual Craig-Hallum Alpha Select Conference will take place on November 17, 2022, in New York City, featuring investor one-on-one meetings. Additionally, the BTIG Digital Health Forum is scheduled for November 21, 2022, as a virtual event, where President Rick Anderson will discuss digital therapeutics at 11:55 a.m. EST. DarioHealth focuses on digital solutions for chronic condition management, delivering personalized care through analytics and coaching.
DarioHealth Corp. (Nasdaq: DRIO) reported third quarter 2022 revenues of $6.6 million, a 17.3% increase from the previous year, driven by strong B2B growth, which now constitutes 63.5% of total revenue. The net loss decreased by 30.3% to $15.6 million. Notably, the company signed 85 B2B contracts valued at over $61 million, with a goal of reaching 100 by year-end. Operating expenses fell by 29.8%, contributing to improved financial health and gross margins of approximately 70% in the B2B segment. A conference call will be held on November 15, 2022.
DarioHealth Corp. (NASDAQ: DRIO) will announce its financial results for Q3 2022 on November 14, 2022, after market close. A conference call and webcast detailing these results will take place on November 15, 2022, at 8:30 am ET. The call will feature executives including CEO Erez Raphael and CFO Zvi Ben-David. Interested participants can join by dialing 1-844-826-3035 (domestic) or 1-412-317-5195 (international) with Conference ID 10173311. The replay will be available until December 15, 2022.
DarioHealth Corp. (Nasdaq: DRIO) has secured its first government contract with a Midwestern city to provide digital therapeutic solutions addressing chronic conditions for several thousand city employees. The contract, set to commence in Q1 2023, aims to enhance employee health in diabetes, hypertension, weight management, and behavioral health. This partnership expands Dario's employer footprint, supporting the City’s employee health strategy while aiming for better health outcomes at lower costs.
DarioHealth Corp. (NASDAQ: DRIO) presented new research at the IASP 2022 World Congress on Pain, highlighting the effectiveness of its biofeedback posture trainer in reducing back pain. The study, involving nearly 1,000 participants, found a direct correlation between increased usage of the device and improved posture, leading to reduced pain levels. Dr. Yifat Hershcovitz emphasized the importance of user engagement in achieving positive outcomes. This research furthers Dario's commitment to understanding the mechanisms of clinical improvement in their digital therapeutic solutions.
FAQ
What is the current stock price of DarioHealth (DRIO)?
What is the market cap of DarioHealth (DRIO)?
What is DarioHealth Corp.?
What recent achievements has DarioHealth made?
How does DarioHealth's platform work?
What clinical results support DarioHealth's solutions?
Who are DarioHealth's target customers?
What are the financial prospects for DarioHealth?
What is the significance of DarioHealth's acquisition of Twill?
How does DarioHealth address language barriers in healthcare?
What recent partnerships has DarioHealth announced?
What are the future plans for DarioHealth?
